Background The main cause of death in RA patients is cardiovascular disease . CD36 is a scavenger receptor has been postulated as a molecule involved in the atherogenic process [2,3]. A soluble fraction, sCD36 has been reported and has been proposed as a marker of atherosclerosis and other metabolic diseases [4,5], however, little is known of the pathways involved in these processes in RA.
Objectives The objective of this study was to evaluate the levels of sCD36 and examine the association between clinical characteristics, disease activity and inflammatory markers in patients with RA.
Methods The study groups were composed of 59 patients with RA (ACR/EULAR 2010) vs. 79 controls. sCD36, PCR, FR, Anti-CCP, insulin, TC, TG, HDL-C, VLDL-C, LDL-c were measured by ELISA. Index Disease Activity 28 (DAS-28) C-reactive protein (CRP) was calculated. VSG by Wintrobe method. cIMT using a Class B ultrasonography. Data were analyzed using descriptive statistics, Student t test, chi-square and ANOVA, as appropriate, with SPSS V.23 software.
Results We found high levels of sCD36 in the control group (1861.10 ±6491.42±29.87 vs. 76.71, P<0.01) as well as ESR (21.26±12.79 vs. 13.29±8.85, P<0.01), CRP (8.97±7.32 vs. 7.27±4.11, P<0.01), and VLDL-c (33.36±17.26 vs. 52.21±21.70, P<0.01). sCD36 was positively correlated with the levels of DAS28pCr, PCR, FR, TG, insulin and IMT; negatively with HDL-c. Finally, we note a proportional direct relationship between sCD36 levels and Index Disease Activity 28 by pCr (Fig. 1).
Conclusions High levels of sCD36 were observed in serum from RA patients compared to a control group, as well as a relationship between sCD36 levels and Index Disease Activity 28 by pCr. It could be proposed to sCD36 as a marker of clinical activity of RA, however, more studies are needed to validate our findings and clarify the regulation and the role of sCD36 in RA.
Solomon, D.H., et al., Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation, 2003. 107(9): p. 1303–7.
Freeman, M.W., Scavenger receptors in atherosclerosis. Curr Opin Hematol, 1997. 4(1): p. 41–7.
Silverstein, R.L., Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med, 2009. 76 Suppl 2: p. S27–30.
Handberg, A., et al., Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation, 2006. 114(11): p. 1169–76.
Liani, R., et al., Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med, 2012. 52(8): p. 1318–24.
Disclosure of Interest None declared